Résumé
Background: It has been proposed that a history of suicide attempts could be a correlate of severe depressive disorder and that suicide attempters (SA) could represent a particular subtype of subjects suffering from major depressive disorder. We investigated clinical and demographic characteristics associated with SA and tested the hypothesis that a history of suicide attempts predicts poor response to antidepressants. Methods: One-hundred-and-forty-one SA and 670 non-SA subjects with major depressive disorder (MDD) were treated for twelve weeks with escitalopram or nortriptyline in GENDEP, a part-randomized multi-center clinical and pharmacogenetic study. Baseline characteristics were compared using linear and logistic regression. Linear mixed models were used to analyse continuous outcomes during the twelve weeks of follow-up. Results: At baseline, SA subjects suffered from more severe depression (mean Montgomery-Asberg Depression Rating Scale: 30.29 (7.61) vs 28.43 (6.54), p = 0.0002), reported higher level of suicidal ideation (1.21 (0.82) vs 0.73 (0.48), p < 0.0001), had a younger age of onset and experienced more depressive episodes, had higher harm avoidance scores and poorer socio-demographic environment than non-SA individuals. However, during the twelve weeks of treatment and after adjustment for baseline severity of depression there was no difference in treatment response between SA and non-SA. Limitations: Due to its retrospective design, it is possible that more severely depressed subjects might report more suicide attempts than less depressed individuals. Conclusions: While SA differed from non-SA in several clinical and demographic characteristics, the antidepressants were similarly effective in SA as in comparably severely depressed subjects without a history of suicide attempts.
Langue d'origine | English |
---|---|
Pages (de-à) | 131-137 |
Nombre de pages | 7 |
Journal | Journal of Affective Disorders |
Volume | 123 |
Numéro de publication | 1-3 |
DOI | |
Statut de publication | Published - juin 2010 |
Publié à l'externe | Oui |
Note bibliographique
Funding Information:The GENDEP study was funded by a European Commission Framework 6 grant , EC Contract Ref.: LSHB-CT-2003-503428 . Nader Perroud was funded by the Swiss National Science foundation : PASMA-118605 . Lundbeck provided both nortriptyline and escitalopram free of charge for the GENDEP study. GlaxoSmithKline and the Medical Research Council contributed by funding add-on projects in the London center. In its latter stages, GENDEP received additional funding at the Institute of Psychiatry site from the Biomedical Research Center for Mental Health at the Institute of Psychiatry, King's College London and South London and Maudsley NHS Foundation Trust (National Institute for Health Research, Department of Health, UK). The funders had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
ASJC Scopus Subject Areas
- Clinical Psychology
- Psychiatry and Mental health
PubMed: MeSH publication types
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't